絞り込み

16530

広告

Edoxaban improves acute venous thromboembolism while preserving protein C and protein S levels.

著者 Yamazaki H , Yagi S , Torii Y , Amano R , Oomichi Y , Sangawa T , Fukuda D , Kadota M , Ise T , Ueno R , Hara T , Kusunose K , Matsuura T , Tobiume T , Yamaguchi K , Yamada H , Soeki T , Wakatsuki T , Akaike M , Sata M
J Cardiol.2017 Oct 31 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (92view , 0users)

Full Text Sources

It is well known that warfarin inhibits the synthesis of vitamin K-dependent anticoagulants, including thrombin, protein C and S, and factor Xa, leading, paradoxically, to an initial hypercoagulable state. Edoxaban, a direct inhibitor of activated factor X is widely used for the treatment of acute venous thromboembolism (VTE). However, the effect of edoxaban on circulating coagulation factors, in patients with acute VTE, remains unknown.
PMID: 29100817 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード